Document:

Amendment No. 2 to Distribution and Supply Agreement

 Exhibit 10.4 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 AMENDMENT NO. 2 TO DISTRIBUTION AND SUPPLY AGREEMENT 

ViroPharma Incorporated, a Delaware corporation (“Manufacturer”), and Prasco, LLC, an Ohio
limited liability company (“Distributor”), as of this 18th day of August, 2009 (the “Amendment Effective Date”), are hereby entering into this Amendment No. 2 (this “Amendment”) to that certain Distribution
and Supply Agreement by and between Manufacturer and Distributor dated November 30, 2007 (as amended by that Amendment No. 1 to Distribution and Supply Agreement dated June 10, 2008, the
“Supply Agreement”). 
 Manufacturer and Distributor wish to amend the Supply Agreement in
accordance with the terms of this Amendment, and in consideration of the mutual covenants and promises contained in this Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Manufacturer
and Distributor agree as follows: 
 1. Definitions. All capitalized terms not otherwise defined in this Amendment shall
have the definitions assigned to such terms in the Supply Agreement. 
 2. Supply Price. Exhibit 3.1 is hereby
amended by deleting the existing contents of Exhibit 3.1 and replacing them in their entirety with the following: 

Exhibit 3.1 
 PRODUCTS AND SUPPLY PRICE 
 The Supply Price will be as follows: 

 

									
	 Presentation
	  	*** or *** Generic
Entrants	 	 	***or ***Generic
Entrants	 
	 125 mg
	  	$	*	** 	 	$	*	** 
	 250 mg
	  	$	*	** 	 	$	*	** 

 Prices are listed per finished carton of Product. Each finished carton of Product will contain two blister packs of ten
capsules of Product. 
 For the purposes hereof, the term “Generic Entrant” means a Third Party who is selling a generic
version of the Branded Product (a) to a wholesaler or distributor for sale in the Territory, or (b) to a consumer in the Territory. The Parties shall keep each other informed and reasonably agree to the number and identity of Generic
Entrants and the date that any Third Party becomes a Generic Entrant. 
 The Supply Price will be reduced for a dosage form of the Product as
provided in this Exhibit 3.1 effective as of the date that the Parties agree that a *** Generic Entrant exists (“Reduction Date”). Within *** (***) days after the Reduction Date, Distributor will provide Manufacturer an Inventory Report
setting forth the number of finished cartons of that dosage form of the Product in its inventory as of the Reduction Date, and Manufacturer will give Distributor a credit equal to such number of finished cartons times the applicable price reduction.
Upon the expiration or termination of this Agreement, Manufacturer will pay Distributor the amount of any such credit that is unused as of such expiration or termination.” 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

3. Limited Waiver. Each of the Parties hereby waives, to the extent implicated by Section 2 of this Amendment, but no further,
the application of the provisions of Section 3.1(c) of the Supply Agreement, which state that, in no event, shall the Supply Price be less than Manufacturer’s Actual Cost. This waiver shall not be extended to any other facts or
circumstances, or to any other rights or obligations arising under the Agreement. Without limiting the generality of the foregoing, this waiver shall not have any effect on the Parties’ rights and obligations set forth in Section 10.3(b)
of the Agreement (providing for termination rights in the event of a significant selling price decrease). 
 4. Termination
For Delayed Launch. The parties hereby amend Sections 10.2(a) and 10.3(a) of the Supply Agreement to delete the words “December 31, 2009” and substitute in lieu thereof the words “December 31, 2010”. 

5. No Other Changes; Execution. Except as explicitly set forth in this Amendment, no amendment or modification to the Supply
Agreement is hereby made. All references to “this Agreement” in the Supply Agreement shall mean the Supply Agreement as amended by this Amendment. This Amendment may be executed in counterparts, each of which shall be deemed an original,
but all of which, together, shall constitute one instrument. This Amendment may be delivered by facsimile. 
 IN WITNESS
WHEREOF, the parties hereto have caused this Amendment to be executed as of the Amendment Effective Date set forth above 
  

			
	VIROPHARMA INCORPORATED
		
	By:	 	 /s/ Daniel B. Soland

 
			
	Name:	 	 Daniel B. Soland

 
			
	Title:	 	 Vice President, Chief Operating Officer

 
			
	
	PRASCO, LLC
		
	By:	 	 /s/ E. Thomas Arington

 
			
	Name:	 	 E. Thomas Arington

 
			
	Title:	 	 CEOAmendment No. 3 to Distribution and Supply Agreement

 Exhibit 10.5 
 AMENDMENT NO. 3 TO 
 DISTRIBUTION AND SUPPLY AGREEMENT 

This Amendment No. 3 to Distribution and Supply Agreement (this “Amendment”) is made as of November 30, 2010, by and
among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”). 

Manufacturer and Distributor are parties to a Distribution and Supply Agreement dated as of November 30, 2007, as amended (the
“Supply Agreement”) and wish to amend the Supply Agreement on the terms of this Agreement. 
 Manufacturer and
Distributor agree as follows: 
  

	 	1.	Termination for Delayed Launch. The parties hereby amend Sections 10.2(a) and 10.3(a) of the Supply Agreement to delete the words “December 31, 2010” and
substitute in lieu thereof the words “December 31, 2011”. 

  

	 	2.	Subject to the above amendment, the Supply Agreement shall continue on its terms. All references to “this Agreement” in the Supply Agreement shall mean the
Supply Agreement as modified hereby and from time to time hereafter. This Amendment may be executed in counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Amendment has been executed in
and will be governed as to validity, interpretation and effect by the laws of the Commonwealth of Pennsylvania, without regard to principles of conflict of laws. 

 Manufacturer and Distributor have caused this Amendment to be duly executed as of the date first written above. 

 

			
	VIROPHARMA INCORPORATED
		
	By:	 	 /s/ Daniel B. Soland

 
			
	Name:	 	Daniel B. Soland
	Title:	 	Vice President and COO

 
			
	
	PRASCO, LLC
		
	By:	 	 /s/ Christopher H. Arington

 
			
	Name:	 	Christopher H. Arington
	Title:	 	PresidentAmendment No. 4 to Distribution and Supply Agreement

 Exhibit 10.6 
 AMENDMENT NO. 4 TO 
 DISTRIBUTION AND SUPPLY AGREEMENT 

This Amendment No. 4 to Distribution and Supply Agreement (this “Amendment”) is made as of November 30, 2011, by and
among ViroPharma Incorporated, a Delaware corporation (hereinafter referred to as “Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”). 

Manufacturer and Distributor are parties to a Distribution and Supply Agreement dated as of November 30, 2007, as amended (the
“Supply Agreement”) and wish to amend the Supply Agreement on the terms of this Agreement. 
 Manufacturer and
Distributor agree as follows: 
  

	 	1.	Termination for Delayed Launch. The parties hereby amend Sections 10.2(a) and 10.3(a) of the Supply Agreement to delete the words “December 31, 2011” and
substitute in lieu thereof the words “December 31, 2012”. 

  

	 	2.	Subject to the above amendment, the Supply Agreement shall continue on its terms. All references to “this Agreement” in the Supply Agreement shall mean the
Supply Agreement as modified hereby and from time to time hereafter. This Amendment may be executed in counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Amendment has been executed in
and will be governed as to validity, interpretation and effect by the laws of the Commonwealth of Pennsylvania, without regard to principles of conflict of laws. 

 Manufacturer and Distributor have caused this Amendment to be duly executed as of the date first written above. 

 

			
	VIROPHARMA INCORPORATED
		
	By:	 	 /s/ Daniel B. Soland

 
			
	Name:	 	Daniel B. Soland
	Title:	 	Vice President and COO

 
			
	
	PRASCO, LLC
		
	By:	 	 /s/ Christopher H. Arington

 
			
	Name:	 	Christopher H. Arington
	Title:	 	PresidentCompensation Clawback Policy

 EXHIBIT 10.1 
 COMPENSATION CLAWBACK POLICY 
 Each executive officer shall repay or forfeit, to the
fullest extent permitted by law and as directed by the Board of Directors of the Company (the “Board”), any annual incentive or other performance-based compensation awards (“Awards”) received by him or her on or after
January 1, 2012 if: 
  

	 	•	 	 the payment, grant or vesting of the Awards was based on the achievement of financial results that were subsequently the subject of a restatement of
the Company’s financial statements filed with the Securities and Exchange Commission, 

  

	 	•	 	 the Board determines in its sole discretion, exercised in good faith, that the executive officer engaged in fraud or misconduct that caused or
contributed to the need for the restatement, 

  

	 	•	 	 the amount of the compensation that would have been received by the executive officer had the financial results been properly reported would have been
lower than the amount actually received, and 

  

	 	•	 	 the Board determines in its sole discretion that it is in the best interests of the Company and its shareholders for the executive officer to repay or
forfeit all or any portion of the Awards. 

 The Board’s independent directors, as identified pursuant to applicable
exchange listing standards, shall have full and final authority to make all determinations under this Policy, including without limitation whether the Policy applies and if so, the amount of the Awards to be repaid or forfeited by the executive
officer. Repayment can be made from the proceeds of the sale of Company stock and the forfeiture of other outstanding awards. All determinations and decisions made by the Board’s independent directors pursuant to the provisions of this Policy
shall be final, conclusive and binding on all persons, including the Company, its affiliates, its shareholders and employees. 
 Each award
agreement or other document setting forth the terms and conditions of any annual incentive or other performance-based award granted to an executive officer shall be deemed to include the provisions of this Policy. The remedy specified in this policy
shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to the Company. 
 The
Board acknowledges that this Policy will be amended if and as required to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act. The Company shall seek to recover incentive compensation paid to any executive officer as required
by the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act or any other “clawback” provision required by law or the listing standards of the NASDAQ Global Select Market. 

As adopted by the Board of Directors of the Company on August 7, 2012.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]